Table 3: Rates of pCR according to HR status.

Study (ref.)Neoadjuvant regimenpCR rate HR+pCR rate HR−

NeoSphere [18](i) Docetaxel + trastuzumab—(arm A)
(ii) Docetaxel + trastuzumab + pertuzumab (arm B)
(iii) Trastuzumab + pertuzumab (arm C)
(iv) Docetaxel + pertuzumab (arm D)
20%
26%
5.9%
17.4%
36.8%
63.2%
27.3%
30%
NR
Neo-ALTTO [12] (i) Weekly P + trastuzumab
(ii) Weekly P + lapatinib
(iii) Weekly P + trastuzumab + lapatinib
22.7%
16.1%
41.6%
36.5%
33.7%
61.3%
NR
CHER-LOB [14, 19](i) CT + trastuzumab
(ii) CT + lapatinib
(iii) CT + trastuzumab + lapatinib
25%
22.7%
35.7%
26.6%
35.7%
56.2%
NR
Buzdar et al. [4] (i) CT + trastuzumab
(ii) CT alone
61.5%
27.2%
70%
25%
NR
NOAH [20]*(i) CT + trastuzumab
(ii) CT alone
18%
17%
48%
22%
0.51
0.002
REMAGUS 02 [9](i) CT + trastuzumab
(ii) CT alone
20.5%
20.5%
32%
19%
NR
NSABP B-41 [15] (i) CT + trastuzumab
(ii) CT + lapatinib
(iii) CT + trastuzumab + lapatinib
46.7%
48%
55.6%
65.5%
60.6%
73%
NR

ER positive versus ER negative, pCR: pathological complete response; HR: hormone receptors; P: paclitaxel; CT: chemotherapy; NR: not reported; ER: estrogen receptors.